Foundation Medicine, Inc., a commercial-stage company, offers products enabled by its molecular information platform to physicians and biopharmaceutical companies. The company’s platform includes proprietary methods and algorithms for analyzing specimens across all types of cancer, and for incorporating that information into clinical care in a concise and user-friendly fashion. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The company’s primary clinical products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, myeloma, and many sarcomas and pediatric cancers, are, to its knowledge, the available comprehensive genomic profiles designed for use in the routine care of patients with cancer. The company is continuing to expand its sales force, grow its molecular information knowledgebase, called FoundationCORE, publish scientific and medical advances, foster relationships throughout the oncology community. Proposed Strategic Collaboration In 2015, the company announced a proposed broad, strategic collaboration with Roche Holdings, Inc., or Roche, and certain of its affiliates, in the field of molecular information for oncology. Strategy The key elements of the company’s strategy are to drive awareness and adoption of its suite of molecular information products including FoundationOne, FoundationOne Heme, FoundationACT, and future products it might develop; empower the broader cancer community with molecular information; demonstrate the value of its products to patients, physicians, and payors;enable biopharmaceutical companies to more effectively develop new cancer therapies; and invest in product enhancements and new product innovations. Patents The company’s patent portfolio includes a single issued U.S. patent, pending U.S. provisional and utility applications, and strategically focused corresponding international applications filed via the Patent Cooperation Treaty, and foreign national and regional counterpart applications. Trade Secrets and Trademarks Foundation Medicine, FoundationOne, Interactive Cancer Explorer, Once. And for All, and The Molecular Information Company are all registered trademarks of the company in the United States, and various of these marks are at various stages of the registration process in other countries. ICE 2, FoundationCORE and PatientMatch are also trademarks of the company. Research and Development For the year ended December 31, 2015, the company’s research and development expenses were $43.9 million. Competition The company’s competitors include laboratory companies such as Bio-Reference Laboratories, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Molecular Health, Caris Life Sciences, Guardant Health, Paradigm, NeoGenomics Laboratories, as well as companies that manufacture or may manufacture diagnostic testing kits such as Abbott Laboratories, Qiagen N.V. and Sequenom, Inc. Significant Events In June 2014, Foundation Medicine, Inc. and AstraZeneca announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza(olaparib) to support its global development program. History Foundation Medicine, Inc. was founded in 2009. The company was incorporated under the laws of the state of Delaware in 2009.
foundation medicine inc (FMI:NASDAQ GS)
150 Second Street
Cambridge, MA 02141
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for FMI.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact FOUNDATION MEDICINE INC, please visit www.foundationmedicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.